Imbrave050: Phase 3 Study of Adjuvant Atezolizumab plus Bevacizumab vs Active Surveillance in Patients with Hepatocellular Carcinoma at High Risk of Disease Recurrence after Resection or Ablation

被引：0
|
作者：
Yopp, Adam Charles
Cheng, Ann-Lii
Kaseb, Ahmed Omar
机构：
[1] UT Southwestern Med Ctr, Dallas, TX USA
[2] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[3] MD Anderson, Houston, TX USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS | 2023年 / 237卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：S19 / S19
页数：1
相关论文
共 50 条
  • [31] Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
    Galle, Peter R.
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Zhu, Andrew X.
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Mulla, Sohail
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Ding, Beiying
    Liu, Juan
    Huang, Chen
    Lim, Ho Yeong
    Cheng, Ann-Lii
    Ducreux, Michel
    LANCET ONCOLOGY, 2021, 22 (07): : 991 - 1001
  • [32] Letter regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"
    Hatanaka, Takeshi
    Hiraoka, Atsushi
    Tada, Toshifumi
    Kakizaki, Satoru
    LIVER CANCER, 2024, 13 (06) : 669 - 670
  • [33] Treatment Duration of Adjuvant Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Patients at High Risk of Recurrence after Resection: A Prospective, Multicentric Cohort Study
    Su, Jia-Yong
    Liu, Shao-Ping
    Xu, Xiao-Ling
    Ou, Jun-Jie
    Ye, Po-Hua
    Zhao, Bin-Tong
    Chen, Jia-Song
    Luo, Qiu-Mei
    Liu, Jin-Rong
    Tang, Fei-Min
    Li, Jian-Rong
    Yang, Da-Long
    Deng, Zhu-Jian
    Pan, Li-Xin
    Li, Yao-Jie
    Li, Le
    Qin, Zhen-Ming
    Liang, Xiu-Mei
    Ma, Yi-Li
    Ma, Liang
    Zhong, Jian-Hong
    LIVER CANCER, 2024,
  • [34] Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: a real-world experience
    Zhang, Shenyu
    Yang, Guibin
    Song, Ruipeng
    Wang, Wei
    Meng, Fanzheng
    Yin, Dalong
    Wang, Jiabei
    Zhang, Shugeng
    Cai, Wei
    Liu, Yao
    Luo, Dayong
    Wang, Jizhou
    Liu, Lianxin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [35] Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"
    Kudo, Masatoshi
    Tsuchiya, Kaoru
    Yamashita, Tatsuya
    Koga, Hironori
    Nakagawa, Yuki
    Ikeda, Masafumi
    LIVER CANCER, 2024, 13 (06) : 671 - 673
  • [36] ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection.
    Mao, Xianhai
    Duan, Xiaohui
    Wu, Dongde
    Zhou, Cuncai
    Tian, Yifeng
    Zheng, Jinfang
    Fu, Changbo
    Xu, Guohui
    Bai, Yannan
    Wu, Changxiong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS632 - TPS632
  • [37] Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Nishikawa, Hiroki
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Koshiyama, Yuichi
    Toyoda, Hidenori
    Ogawa, Chikara
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Kawata, Kazuhito
    Ohama, Hideko
    Tada, Fujimasa
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Nishimura, Takashi
    Imai, Michitaka
    Kosaka, Hisashi
    Naganuma, Atsushi
    Matono, Tomomitsu
    Aoki, Tomoko
    Kuroda, Hidekatsu
    Yata, Yutaka
    Koizumi, Yohei
    Nakamura, Shinichiro
    Enomoto, Hirayuki
    Kaibori, Masaki
    Hiasa, Yoichi
    Kudo, Masatoshi
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (02) : 233 - 245
  • [38] Adjuvant TACE plus lenvatinib as compared with TACE alone in patients with hepatocellular carcinoma at high risk of recurrence after surgery: A prospective controlled study.
    Zhang, Bin
    Jin, Renan
    Xu, Junjie
    Chen, Ming Yu
    Chen, Jiang
    Zhu, Hepan
    Cao, Jiasheng
    Song, Chao
    Yang, Zaibo
    Zhang, Yewei
    Liang, Xiao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 505 - 505
  • [39] IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection
    Bex, A.
    Uzzo, R.
    Karam, J. A.
    Master, V. A.
    Donskov, F.
    Suarez, C.
    Albiges, L.
    Rini, B. I.
    Tomita, Y.
    Kann, A.
    Procopio, G.
    Massari, F.
    Zibelman, M.
    Antonyan, I.
    Huseni, M.
    Basu, D.
    Ci, B.
    Leung, W.
    Khan, O.
    Pal, S. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1431 - S1432
  • [40] IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Mertens, Joachim
    Kim, Tae-You
    Kudo, Masatoshi
    Lim, Ho Yeong
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Feng, Yin-Hsun
    Verret, Wendy
    Nicholas, Alan
    Li, Lindong
    Ma, Ning
    Zhu, Andrew X.
    Cheng, Ann-Lii
    SWISS MEDICAL WEEKLY, 2021, 151 : 25 - 26
12345